2024-19720. Medical Devices; Neurological Devices; Classification of the Digital Therapy Device for Attention Deficit Hyperactivity Disorder
Table 1—Digital Therapy Device for Attention Deficit Hyperactivity Disorder Risks and Mitigation Measures
Identified risks to health Mitigation measures Ineffective treatment leading to worsening or uncontrolled symptoms Clinical performance testing, and Labeling. Device software failure leading to delayed access Software verification and validation, and Labeling. Treatment results in frustration, emotional reaction, dizziness, nausea, headache, eye-strain, or joint pain Labeling; Clinical performance testing; and Software verification, validation, and hazard analysis. Treatment results in seizure Labeling, and Clinical performance testing. Treatment results in screen addiction Labeling, and Clinical performance testing. Treatment results in decreased sleep quality Labeling, and Clinical performance testing.
Document Information
- Effective Date:
- 9/3/2024
- Published:
- 09/03/2024
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Action:
- Final amendment; final order.
- Document Number:
- 2024-19720
- Dates:
- This order is effective September 3, 2024. The classification was applicable on June 15, 2020.
- Pages:
- 71155-71156 (2 pages)
- Docket Numbers:
- Docket No. FDA-2024-N-3992
- Topics:
- Medical devices
- PDF File:
- 2024-19720.pdf
- CFR: (1)
- 21 CFR 882